Darinasparsin is being investigated for use/treatment in blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), solid tumors, multiple myeloma, and liver cancer. Darinaparsin was developed by Solasia Pharma and Ziopharm Oncology.
The API has now reached off-patent status, after being launched in 2022.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Darinaparsin and many others, contact info@pharmacheminvestor.com